Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches
Microneedles (MNs) are a prospective system in cancer immunotherapy to overcome barriers regarding proper antigen delivery and presentation. This study aims at identifying the potential of MNs for the delivery of Peptide-coated Conditionally Replicating Adenoviruses (PeptiCRAd), whereby peptides enh...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
KeAi Communications Co., Ltd.
2025-03-01
|
| Series: | Bioactive Materials |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452199X24004900 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832586270033838080 |
|---|---|
| author | Carmine D'Amico Manlio Fusciello Firas Hamdan Federica D'Alessio Paolo Bottega Milda Saklauskaite Salvatore Russo Justin Cerioni Khalil Elbadri Marianna Kemell Jouni Hirvonen Vincenzo Cerullo Hélder A. Santos |
| author_facet | Carmine D'Amico Manlio Fusciello Firas Hamdan Federica D'Alessio Paolo Bottega Milda Saklauskaite Salvatore Russo Justin Cerioni Khalil Elbadri Marianna Kemell Jouni Hirvonen Vincenzo Cerullo Hélder A. Santos |
| author_sort | Carmine D'Amico |
| collection | DOAJ |
| description | Microneedles (MNs) are a prospective system in cancer immunotherapy to overcome barriers regarding proper antigen delivery and presentation. This study aims at identifying the potential of MNs for the delivery of Peptide-coated Conditionally Replicating Adenoviruses (PeptiCRAd), whereby peptides enhance the immunogenic properties of adenoviruses presenting tumor associated antigens. The combination of PeptiCRAd with MNs containing polyvinylpyrrolidone and sucrose was tested for the preservation of structure, induction of immune response, and tumor eradication. The findings indicated that MN-delivered PeptiCRAd was effective in peptide presentation in vivo, leading to complete tumor rejection when mice were pre-vaccinated. A rise in the cDC1 population in the lymph nodes of the MN treated mice led to an increase in the effector memory T cells in the body. Thus, the results of this study demonstrate that the combination of MN technology with PeptiCRAd may provide a safer, more tolerable, and efficient approach to cancer immunotherapy, potentially translatable to other therapeutic applications. |
| format | Article |
| id | doaj-art-746be62b7b244a3983e467412beabd78 |
| institution | Kabale University |
| issn | 2452-199X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | KeAi Communications Co., Ltd. |
| record_format | Article |
| series | Bioactive Materials |
| spelling | doaj-art-746be62b7b244a3983e467412beabd782025-01-26T05:04:20ZengKeAi Communications Co., Ltd.Bioactive Materials2452-199X2025-03-0145115127Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patchesCarmine D'Amico0Manlio Fusciello1Firas Hamdan2Federica D'Alessio3Paolo Bottega4Milda Saklauskaite5Salvatore Russo6Justin Cerioni7Khalil Elbadri8Marianna Kemell9Jouni Hirvonen10Vincenzo Cerullo11Hélder A. Santos12Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland; Corresponding author.Department of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5, E00790, Helsinki, Finland; Corresponding author.Department of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5, E00790, Helsinki, FinlandDepartment of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5, E00790, Helsinki, FinlandDepartment of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5, E00790, Helsinki, FinlandDepartment of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5, E00790, Helsinki, FinlandDepartment of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5, E00790, Helsinki, FinlandDepartment of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5, E00790, Helsinki, FinlandDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, FinlandDepartment of Chemistry, Faculty of Science, University of Helsinki, FI-00014, Helsinki, FinlandDrug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, FinlandDepartment of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5, E00790, Helsinki, Finland; Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Fabianinkatu 33, 00710, Helsinki, Finland; Translational Immunology Program (TRIMM), Faculty of Medicine Helsinki University, University of Helsinki, Haartmaninkatu 8, 00290, Helsinki, Finland; Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, 00014, Helsin-ki, Finland; Department of Molecular Medicine and Medical Biotechnology and CEINGE, Naples University Federico II, 80131, Naples, Italy; Corresponding author. Department of Pharmaceutical Biosciences, University of Helsinki, Faculty of Pharmacy ImmunoViroTherapy Lab, Drug Research Program, Viikinkaari 5, E00790, Helsinki, Finland.Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland; Department of Biomaterials and Biomedical Technology, The Personalized Medicine Research Institute (PRECISION), University Medical Center Groningen (UMCG), University of Groningen, 9713 AV, Groningen, the Netherlands; Corresponding author. Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, FI-00014, Helsinki, Finland.Microneedles (MNs) are a prospective system in cancer immunotherapy to overcome barriers regarding proper antigen delivery and presentation. This study aims at identifying the potential of MNs for the delivery of Peptide-coated Conditionally Replicating Adenoviruses (PeptiCRAd), whereby peptides enhance the immunogenic properties of adenoviruses presenting tumor associated antigens. The combination of PeptiCRAd with MNs containing polyvinylpyrrolidone and sucrose was tested for the preservation of structure, induction of immune response, and tumor eradication. The findings indicated that MN-delivered PeptiCRAd was effective in peptide presentation in vivo, leading to complete tumor rejection when mice were pre-vaccinated. A rise in the cDC1 population in the lymph nodes of the MN treated mice led to an increase in the effector memory T cells in the body. Thus, the results of this study demonstrate that the combination of MN technology with PeptiCRAd may provide a safer, more tolerable, and efficient approach to cancer immunotherapy, potentially translatable to other therapeutic applications.http://www.sciencedirect.com/science/article/pii/S2452199X24004900MicroneedlesCancer therapyAdenoviral vectorVaccine |
| spellingShingle | Carmine D'Amico Manlio Fusciello Firas Hamdan Federica D'Alessio Paolo Bottega Milda Saklauskaite Salvatore Russo Justin Cerioni Khalil Elbadri Marianna Kemell Jouni Hirvonen Vincenzo Cerullo Hélder A. Santos Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches Bioactive Materials Microneedles Cancer therapy Adenoviral vector Vaccine |
| title | Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches |
| title_full | Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches |
| title_fullStr | Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches |
| title_full_unstemmed | Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches |
| title_short | Transdermal delivery of PeptiCRAd cancer vaccine using microneedle patches |
| title_sort | transdermal delivery of pepticrad cancer vaccine using microneedle patches |
| topic | Microneedles Cancer therapy Adenoviral vector Vaccine |
| url | http://www.sciencedirect.com/science/article/pii/S2452199X24004900 |
| work_keys_str_mv | AT carminedamico transdermaldeliveryofpepticradcancervaccineusingmicroneedlepatches AT manliofusciello transdermaldeliveryofpepticradcancervaccineusingmicroneedlepatches AT firashamdan transdermaldeliveryofpepticradcancervaccineusingmicroneedlepatches AT federicadalessio transdermaldeliveryofpepticradcancervaccineusingmicroneedlepatches AT paolobottega transdermaldeliveryofpepticradcancervaccineusingmicroneedlepatches AT mildasaklauskaite transdermaldeliveryofpepticradcancervaccineusingmicroneedlepatches AT salvatorerusso transdermaldeliveryofpepticradcancervaccineusingmicroneedlepatches AT justincerioni transdermaldeliveryofpepticradcancervaccineusingmicroneedlepatches AT khalilelbadri transdermaldeliveryofpepticradcancervaccineusingmicroneedlepatches AT mariannakemell transdermaldeliveryofpepticradcancervaccineusingmicroneedlepatches AT jounihirvonen transdermaldeliveryofpepticradcancervaccineusingmicroneedlepatches AT vincenzocerullo transdermaldeliveryofpepticradcancervaccineusingmicroneedlepatches AT helderasantos transdermaldeliveryofpepticradcancervaccineusingmicroneedlepatches |